{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T11:23:33Z","timestamp":1790940213797,"version":"4.1.0"},"reference-count":26,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2005,5,10]],"date-time":"2005-05-10T00:00:00Z","timestamp":1115683200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2005,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Bortezomib is a proteasome inhibitor with manageable clinical toxicity and laboratory evidence of anti\u2010melanoma activity. Therefore, it was considered for clinical testing in patients with metastatic melanoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with metastatic melanoma and adequate hematologic, renal, and hepatic function were treated with bortezomib (a 1.5\u2010mg\/m<jats:sup>2<\/jats:sup> intravenous bolus twice weekly for 2 of every 3 weeks). Eligible patients were age \u2265 18 years with an Eastern Cooperative Oncology Group performance status of 0\u20131. The primary goal of the current study was to evaluate the 18\u2010week disease progression\u2010free survival rate and tolerability of bortezomib in these patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The current study was intended to treat 45 patients. It was closed at the planned interim analysis due to early evidence of insufficient clinical efficacy. Twenty\u2010seven patients with a median age of 56 years (range, 32\u201377 years)were accrued. There were no major clinical responses to treatment. Only 6 patients (22%) achieved stable disease. Of these 6 patients, 4 were still stable after 4 cycles of treatment, but were removed from the study due to toxicity. The median time to disease progression was 1.5 months (95% confidence interval [95% CI], 1.4\u20131.6) with a median overall survival of 14.5 months (95% CI, 9\u201322). Having failed bortezomib, most patients proceeded to other clinical trials. Twenty\u2010six patients were evaluable for toxicity. One patient was removed from the study for other reasons and could not return for the cycle evaluation and thus was never evaluated. Of the 26 patients, no Grade 4\/5 treatment\u2010related toxicities (using the National Cancer Institute Common Toxicity Criteria [version 2.0]) were reported. Eleven patients (42%) had Grade 3 toxicities (believed to be at least possibly related to treatment), including sensory neuropathy, thrombocytopenia, constipation, fatigue, ileus, abdominal pain, and infection without neutropenia. The median number of treatment cycles patients received was two (range, one to six treatment cycles). Two patients (7%) had 1 dose delay and 6 patients (22%) had dose reductions during 1 treatment cycle due to adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Single\u2010agent bortezomib, administered twice weekly \u00d7 2 weeks, every 3 weeks at a dose of 1.5 mg\/m<jats:sup>2<\/jats:sup>, was not found to be effective in the treatment of patients with metastatic melanoma. Cancer 2005. \u00a9 2005 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21108","type":"journal-article","created":{"date-parts":[[2005,5,10]],"date-time":"2005-05-10T18:46:43Z","timestamp":1115750803000},"page":"2584-2589","source":"Crossref","is-referenced-by-count":108,"title":["A phase II study of bortezomib in the treatment of metastatic malignant melanoma"],"prefix":"10.1002","volume":"103","author":[{"given":"Svetomir N.","family":"Markovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fitzroy","family":"Dawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sharfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Albertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Maples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Fracasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Fitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"LoRusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Erlichman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,6,2]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1367-5931(02)00343-5"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401812"},{"key":"e_1_2_5_4_2","first-page":"2638","article-title":"The proteasome inhibitor PS\u2010341 in cancer therapy","volume":"5","author":"Teicher BA","year":"1999","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0093-7754(01)90034-X"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.01.133"},{"key":"e_1_2_5_7_2","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies","volume":"8","author":"Aghajanian C","year":"2002","journal-title":"Clin Cancer Res."},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5293.1652"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-56373-7_5"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5293.1672"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(94)90482-0"},{"key":"e_1_2_5_12_2","first-page":"219","article-title":"Adhesion molecules in tumor metastasis","volume":"4","author":"Zetter BR","year":"1993","journal-title":"Semin Cancer Biol."},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1159\/000068624"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1096-7192(02)00146-4"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2002.tb00309.x"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(03)00080-X"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030288"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_5_19_2","first-page":"627","article-title":"Report of a phase II study of proteasome inhibitor bortezomib (VELCADE\u2122) in patients with relapsed or refractory indolent or aggressive lymphomas","volume":"102","author":"Goy A","year":"2003","journal-title":"Blood."},{"key":"e_1_2_5_20_2","first-page":"3358","article-title":"A phase II study of bortezomib in patients with mantle cell lymphoma","volume":"102","author":"Assouline S","year":"2003","journal-title":"Blood."},{"key":"e_1_2_5_21_2","doi-asserted-by":"crossref","first-page":"652s","DOI":"10.1200\/jco.2004.22.90140.7145","article-title":"Effects of bortezomib (PS\u2010341) on NF\u2010\u03baB activation in peripheral blood mononuclear cells (PBMCs) of advanced non\u2010small lung cancer (NSCLC) patients: a phase IV pharmacodynamic trial","volume":"22","author":"Stevenson JP","year":"2004","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.1150"},{"key":"e_1_2_5_23_2","first-page":"3535","article-title":"Enhanced chemosensitivity to CPT\u201011 with proteasome inhibitor PS\u2010341: implications for systemic nuclear factor\u2010kappaB inhibition","volume":"61","author":"Cusack JC","year":"2001","journal-title":"Cancer Res."},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.2001.6194"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2002.n.011"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-200110000-00013"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01446-8"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21108","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:04:02Z","timestamp":1760277842000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,2]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,6,15]]}},"alternative-id":["10.1002\/cncr.21108"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21108","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,2]]}}}